Denmark-based Novo Nordisk plans to acquire Inversago Pharma for up to $1.8 billion dollars, depending on whether the clinical-stage obesity drugmaker meets certain development and sales milestones.
Read the full post on Becker's Hospital Review - Healthcare News
